WINT Windtree Therapeutics

Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space

Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space

Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions

CommLoan, Inc. is a tech company focused on transforming the way middle market loans are originated

CommLoan has streamlined the process of obtaining commercial real estate financing

WARRINGTON, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed a letter of intent to acquire CommLoan, Inc., a commercial tech finance company.

CommLoan will retain key employees and become a subsidiary of Windtree. Windtree has provided bridge financing to CommLoan during this transition period.

“Windtree is pleased to add a revenue generating fintech business as our subsidiary,” said Jed Latkin, Chief Executive Officer of Windtree. “We have spent several quarters trying to find the right business to spearhead our growth initiatives and we are very enthusiastic that CommLoan provides us with a unique advantage to seize on the growing trend in using software and AI to streamline the lending process. CommLoan has put together a massive proprietary database that would take years to replicate and creates a massive moat between them and the other companies trying to compete in this space.”

"We’ve spent years developing technology that revolutionizes how commercial real estate loans are originated. Joining forces with Windtree positions us to accelerate that mission while maintaining control of our long-term direction. This marks an exciting new chapter for CommLoan as we prepare for rapid expansion and the path ahead," said Mitch Ginsberg, CEO and Founder of CommLoan.

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. is a diversified company with several divisions and focused on becoming a revenue generating company with future profitability.

About CommLoan, Inc.

CommLoan is a commercial real estate lending technology company operating the first true commercial mortgage lending marketplace. Through its proprietary platform, CUPID™, CommLoan connects borrowers and originators with hundreds of active lenders nationwide, allowing users to efficiently compare rates, terms, and loan structures across property types, including multifamily, retail, office, industrial, healthcare, and SBA financing. Established in 2014 and headquartered in Scottsdale, Arizona, CommLoan is redefining commercial mortgage lending through technology, transparency, and data-driven efficiency. For more information, visit

Forward Looking Statements

The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company’s ability to begin its environmental services business and manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact Information:

Eric Curtis



EN
03/12/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Windtree Therapeutics

 PRESS RELEASE

Windtree Therapeutics Announces It Has Signed a Letter of Intent to Ac...

Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans are originated CommLoan has streamlined the process of obtaining commercial real estate financing WARRINGTON, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversifi...

 PRESS RELEASE

Windtree Therapeutics Announces It May Receive License Agreement Payme...

Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN®, lyophilized lucinactant and AEROSURF® (a drug and device combination) The franchise is intended to treat premature infants with respiratory distress syndrome (RDS) Windtree will communicate more information abo...

 PRESS RELEASE

Windtree Therapeutics Announces More Strengthening of Its Istaroxime a...

Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada and Mexico The pure SERCA2a activators patent for acute heart failure was granted in Isreal WARRINGTON, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several ...

 PRESS RELEASE

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash a...

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree to acquire Titan Environmental Services, Inc. The executed agreement releases the parties from their reciprocal surviving obligations WARRINGTON, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtr...

 PRESS RELEASE

Windtree Therapeutics Stockholders Approve Key Proposals for Revenue a...

Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environmental services Windtree is choosing to focus on environmental services and other revenue generating businesses – the Company will not move forward with the cryptocurrency treasury strategy Company continues to move forwar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch